trauma. musculoskeletal sysytem and connective tissue diseases
Conditions
Interventions
Intervention 1: intervention group :administration of morphine 0.1 mg /kg +ketamine 0.2 mg/kg in minimum interval of 5 minutes with patient's request and evaluation of pain score and side effects in
120 of study. Intervention 2: control group :administration of morphine 0.1 mg/kg +0.02 ml/kg of sterile water as placebo in minimum interval of 5 minutes with patient's request and evaluation of pai
Treatment - Drugs
intervention group :administration of morphine 0.1 mg /kg +ketamine 0.2 mg/kg in minimum interval of 5 minutes with patient's request and evaluation of pain score and side effects in minutes 0
control group :administration of morphine 0.1 mg/kg +0.02 ml/kg of sterile water as placebo in minimum interval of 5 minutes with patient's request and evaluation of pain score and side effects in mi
Sponsors
researching center of Tehran University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 50 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: patients above 18 years old with trauma only to limbs and severe pain (VAS equal or above 6). stable vital signs including systolic blood pressure equal or above 90 mm HG ; pulse rate between 60 and 120 per minute ; O2 saturation equal or above 90%; GCS =15 ; no addiction to drugs ;no consumption opioids or analgesics before begining of study ;no history of leaver diseases ;renal diseases; respiratory diseases ;cardiovascular diseases ; psychiatric diseases,blood diseases . Exclusion criteria: history of head trauma and contraindications for ketamine or morphine administration ; allergy to morphine or ketamine ; need to regional nerve block ; unable to conception of VAS;no interest to participate in study
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Pain control. Timepoint: 0, 10, 30, 60, 90 and 120 minutes after treatment. Method of measurement: Visual Analogous Scale (VAS). | — |
Secondary
| Measure | Time frame |
|---|---|
| Side effects and changes in vital signs. Timepoint: 30 and 60 minutes after treatment. Method of measurement: Patient monitoring. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr. Mohammad Amin Zare
Tehran University of Medical Sciences
Outcome results
None listed